Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Endocrine 1Breast 1

Conditions

Colorectal Neoplasms 105Carcinoma, Hepatocellular 34Neoplasm Metastasis 19Neoplasms 17Gastrointestinal Stromal Tumors 17Colonic Neoplasms 14Rectal Neoplasms 12Liver Neoplasms 8Glioblastoma 7Sarcoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Cholangiocarcinoma 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × regorafenib × Clear all
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT02053376 2019-01-30

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

University of Pittsburgh

Phase 2 Completed
43 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡